

Appl. No. 10/695,195  
Amdt. dated January 23, 2006  
Reply to Office action of 10/24/2005

This listing of claims will replace all prior versions, and listings, of claims in our amendments or responses to Office actions.

**Listing of Claims:**

Claims 1-20. (Cancelled).

Claim 21. (Previously added) An isolated or recombinant polypeptide comprising SEQ ID NOs:2 or 4.

Claim 22. (Currently amended) The polypeptide of Claim 21, further comprising:

- a) a detectable label;
- b) a glycosylation or phosphorylation; or
- c) a solid substrate.

Claim 23. (Currently amended) A composition comprising the polypeptide of Claim 21 and a carrier, wherein the carrier is:

- a) an aqueous compound, including water, saline, or buffer; or
- b) formulated for oral, rectal, nasal, topical, parenteral, subcutaneous, intramuscular, intravenous, or intradermal administration.

Claim 24. (Currently amended) A kit comprising the polypeptide of Claim 21, and:

- a) a compartment comprising the polypeptide; and/or
- b) instructions for use or disposal of reagents in the kit.

Claim 25. (Withdrawn) A method for producing the polypeptide of Claim 21, comprising:

- a) culturing a cell transformed with a nucleic acid encoding the polypeptide of SEQ ID NOs:2 or 4; and
- b) purifying the polypeptide.

Appl. No. 10/695,195  
Amdt. dated January 23, 2006  
Reply to Office action of 10/24/2005

Claim 26 (New) The polypeptide of Claim 21, wherein the polypeptide is:

- a) glycosylated;
- b) phosphorylated; or
- c) a fusion protein.

Claim 27 (New) The composition of Claim 23, wherein the aqueous compound is:

- a) water;
- b) saline; or
- c) a buffer.